- Home
- ACRV vs ATNM Comparison
ACRV vs ATNM Comparison
Compare ACRV & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- ATNM
- Stock Information
- Founded
- ACRV 2018
- ATNM 2000
- Country
- ACRV United States
- ATNM United States
- Employees
- ACRV N/A
- ATNM N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- ATNM Health Care
- Exchange
- ACRV Nasdaq
- ATNM Nasdaq
- Market Cap
- ACRV 47.8M
- ATNM 50.2M
- IPO Year
- ACRV 2022
- ATNM N/A
- Fundamental
- Price
- ACRV $2.09
- ATNM $1.69
- Analyst Decision
- ACRV Buy
- ATNM Strong Buy
- Analyst Count
- ACRV 6
- ATNM 2
- Target Price
- ACRV $17.75
- ATNM $4.50
- AVG Volume (30 Days)
- ACRV 464.1K
- ATNM 261.2K
- Earning Date
- ACRV 11-12-2025
- ATNM 11-13-2025
- Dividend Yield
- ACRV N/A
- ATNM N/A
- EPS Growth
- ACRV N/A
- ATNM N/A
- EPS
- ACRV N/A
- ATNM N/A
- Revenue
- ACRV N/A
- ATNM N/A
- Revenue This Year
- ACRV N/A
- ATNM N/A
- Revenue Next Year
- ACRV $805.34
- ATNM N/A
- P/E Ratio
- ACRV N/A
- ATNM N/A
- Revenue Growth
- ACRV N/A
- ATNM N/A
- 52 Week Low
- ACRV $1.05
- ATNM $1.03
- 52 Week High
- ACRV $8.74
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- ACRV 65.95
- ATNM 59.80
- Support Level
- ACRV $1.92
- ATNM $1.39
- Resistance Level
- ACRV $2.05
- ATNM $1.54
- Average True Range (ATR)
- ACRV 0.15
- ATNM 0.09
- MACD
- ACRV 0.01
- ATNM 0.01
- Stochastic Oscillator
- ACRV 97.70
- ATNM 88.57
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.